Genomic profiling may identify resected gastric cancers at particularly high recurrence risk, suggesting patients with tumors with KRAS/PIK3CA alterations could be candidates for more intensive perioperative therapy and surveillance, although prospective studies are needed before using these markers to escalate treatment. | Coffey, JAMA Surg 2026
